



**Supplemental Figure 1**- Higher doses of immunotherapy do not induce tumor regression when administrated to large melanoma lesions. **(A)** Tumor size (mm<sup>2</sup>) in mice injected s.c. with B16F10 cells and treated intratumorally with TNF $\alpha$  plus low dose (LD) or high dose (HD) of anti-TRP1 antibodies and CD40L (n=3). **(B)** Tumor size (mm<sup>2</sup>) in mice injected with *ret* melanoma cells and treated intratumorally with TNF $\alpha$  plus low dose (LD) or high dose (HD) of anti-TRP1 antibodies and CD40L (n=3). **(C)** Tumor size (mm<sup>2</sup>) in mice injected s.c. with B16F10 cells and treated daily with intratumoral injection of low dose (LD) or high dose (HD) of CpG and PolyI:C (n=3).